Posted by Michael Wonder on 14 Jul 2021
Harvard doctor urges FDA reforms after Biogen Alzheimer nod
13 July 2021 - Curtail biomarker use for clearance, Kesselheim writes in JAMA.
A prominent Harvard doctor who was one of three experts to quit a U.S. advisory panel after Biogen’s Alzheimer’s drug Aduhelm was approved said regulators should have tougher standards for granting clearances to unproven medications.
